DHX15 and glioblastoma: Given that ‘active’ LOC–DHX15 RNP complex creates a key dependency in IDH-wild-type glioblastoma, targeting this proinflammatory scaffold via the administration of a DHX inhibitor may specifically reverse this phenotype.